Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
In-hospital Outcomes of Healthcare-associated COVID-19 (Omicron) Versus Healthcare-associated Influenza: A Retrospective, Nationwide Cohort Study in Switzerland.
СтатьяСравнительное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Grant Rebecca, de Kraker Marlieke E A, Buetti Niccolò, Jackson Holly, Abbas Mohamed, Sobel Jonathan Aryeh, Sommerstein Rami, Eder Marcus, Balmelli Carlo, Troillet Nicolas, Schreiber Peter W, Jent Philipp, Senn Laurence, Flury Domenica, Tschudin-Sutter Sarah, Buettcher Michael, Süveges Maria, Urbini Laura, Keiser Olivia, Roder Ursina, Harbarth Stephan, Zanella Marie-Céline, CH-SUR Study Group
Аннотация
BACKGROUND: As coronavirus disease 2019 (COVID-19) is integrated into existing infectious disease control programs, it is important to understand the comparative clinical impact of COVID-19 and other respiratory diseases.
METHODS: We conducted a retrospective cohort study of patients with symptomatic healthcare-associated COVID-19 or influenza reported to the nationwide, hospital-based surveillance system in Switzerland. Included patients were adults (aged ≥18 years) hospitalized for ≥3 days in tertiary care and large regional hospitals. Patients had COVID-19 symptoms and a real-time polymerase chain reaction-confirmed severe acute respiratory syndrome coronavirus 2 infection ≥3 days after hospital admission between 1 February 2022 and 30 April 2023, or influenza symptoms and a real-time polymerase chain reaction-confirmed influenza A or B infection ≥3 days after hospital admission between 1 November 2018 and 30 April 2023. Primary and secondary outcomes were 30-day in-hospital mortality and admission to intensive care unit, respectively. Cox regression (Fine-Gray model) was used to account for time dependency and competing events, with inverse probability weighting to adjust for confounding.
RESULTS: We included 2901 patients with symptomatic, healthcare-associated COVID-19 (Omicron) and 868 patients with symptomatic, healthcare-associated influenza from 9 hospitals. We found a similar case fatality ratio between healthcare-associated COVID-19 (Omicron) (6.2%) and healthcare-associated influenza (6.1%) patients; after adjustment, patients had a comparable subdistribution hazard ratio for 30-day in-hospital mortality (0.91; 95% confidence interval, .67-1.24). A similar proportion of patients were admitted to the intensive care unit (2.4% COVID-19; 2.6% influenza).
CONCLUSIONS: COVID-19 and influenza continue to cause severe disease among hospitalized patients. Our results suggest that in-hospital mortality risk of healthcare-associated COVID-19 (Omicron) and healthcare-associated influenza are comparable.
METHODS: We conducted a retrospective cohort study of patients with symptomatic healthcare-associated COVID-19 or influenza reported to the nationwide, hospital-based surveillance system in Switzerland. Included patients were adults (aged ≥18 years) hospitalized for ≥3 days in tertiary care and large regional hospitals. Patients had COVID-19 symptoms and a real-time polymerase chain reaction-confirmed severe acute respiratory syndrome coronavirus 2 infection ≥3 days after hospital admission between 1 February 2022 and 30 April 2023, or influenza symptoms and a real-time polymerase chain reaction-confirmed influenza A or B infection ≥3 days after hospital admission between 1 November 2018 and 30 April 2023. Primary and secondary outcomes were 30-day in-hospital mortality and admission to intensive care unit, respectively. Cox regression (Fine-Gray model) was used to account for time dependency and competing events, with inverse probability weighting to adjust for confounding.
RESULTS: We included 2901 patients with symptomatic, healthcare-associated COVID-19 (Omicron) and 868 patients with symptomatic, healthcare-associated influenza from 9 hospitals. We found a similar case fatality ratio between healthcare-associated COVID-19 (Omicron) (6.2%) and healthcare-associated influenza (6.1%) patients; after adjustment, patients had a comparable subdistribution hazard ratio for 30-day in-hospital mortality (0.91; 95% confidence interval, .67-1.24). A similar proportion of patients were admitted to the intensive care unit (2.4% COVID-19; 2.6% influenza).
CONCLUSIONS: COVID-19 and influenza continue to cause severe disease among hospitalized patients. Our results suggest that in-hospital mortality risk of healthcare-associated COVID-19 (Omicron) and healthcare-associated influenza are comparable.